Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial.
Lancet Oncol
; 15(12): 1397-406, 2014 Nov.
Article
en En
| MEDLINE
| ID: mdl-25439694
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Neoplasias Óseas
/
Radio (Elemento)
/
Taxoides
/
Neoplasias de la Próstata Resistentes a la Castración
Tipo de estudio:
Clinical_trials
/
Diagnostic_studies
Límite:
Aged
/
Aged80
/
Humans
/
Male
/
Middle aged
Idioma:
En
Año:
2014
Tipo del documento:
Article